EGFR Inhibitors

EGFR/ErbB1/HER1

ErbB2/HER2

ErbB3/HER3

ErbB4/HER4

EGFR Degraders, Inducers, Inhibitors, Agonists, Antagonists, Activators & Modulators

Product Name	EGFR/ErbB1/HER1	ErbB2/HER2	ErbB3/HER3	ErbB4/HER4	Purity
Osimertinib	EGFR^L858R, IC₅₀: 12 nM (Enzyme assays) EGFR^L858R/T790M, IC₅₀: 1 nM (Enzyme assays)				99.96%
Trastuzumab		HER2			99.80%
Gefitinib	EGFR				99.94%
Cetuximab	Soluble EGFR, Kd: 0.201 nM EGFR, Kd: 0.147 nM (Fixed A431 cells)				99.70%
Erlotinib	EGFR, IC₅₀: 2 nM (Cell Free Assay)				99.99%
Afatinib	EGFR, IC₅₀: 0.5 nM EGFR^L858R, IC₅₀: 0.4 nM EGFR^L858R/T790M, IC₅₀: 10 nM	HER2, IC₅₀: 14 nM			99.92%
Lapatinib	EGFR, IC₅₀: 10.2 nM (Cell Free Assay)	ErbB2, IC₅₀: 9.8 nM (Cell Free Assay)			99.83%
Genistein	EGFR, IC₅₀: 0.6 μM (Cell Assay)				99.86%
AG490	EGFR				99.92%
Tucatinib		HER2			99.82%
Neratinib	EGFR, IC₅₀: 92 nM	HER2, IC₅₀: 59 nM			99.94%
Disitamab vedotin		HER2			98.75%
Dacomitinib	EGFR, IC₅₀: 6 nM	ErbB2, IC₅₀: 45.7 nM		ErbB4, IC₅₀: 73.7 nM	99.74%
AG-1478	EGFR, IC₅₀: 3 nM				99.22%
Pertuzumab		HER2			99.80%
Osimertinib mesylate	EGFR^L858R/T790M, IC₅₀: 1 nM EGFR^L858R, IC₅₀: 12 nM				99.97%
NSC 228155	EGFR				≥98.0%
Erlotinib Hydrochloride	EGFR, IC₅₀: 2 nM				99.93%
Lazertinib	EGFR^T790M				99.07%
Sapitinib	EGFR, IC₅₀: 4 nM	ErbB2, IC₅₀: 3 nM	HER3, IC₅₀: 4 nM		99.93%
Mobocertinib	EGFR (WT) EGFR exon 20 insertion	HER2			99.60%
Almonertinib	EGFR^T790M, IC₅₀: 0.37 nM EGFR^L858R/T790M, IC₅₀: 0.29 nM EGFR^{del19 T790M}, IC₅₀: 0.21 nM				99.98%
Pyrotinib	EGFR, IC₅₀: 13 nM	HER2, IC₅₀: 38 nM			99.89%
Firmonertinib mesylate	EGFR				99.97%
Icotinib	EGFR, IC₅₀: 5 nM				99.99%
CUDC-101	EGFR, IC₅₀: 2.4 nM	HER2, IC₅₀: 15.7 nM			98.84%
Afatinib dimaleate	EGFR, IC₅₀: 0.5 nM EGFR^L858R, IC₅₀: 0.4 nM EGFR^L858R/T790M, IC₅₀: 10 nM	HER2, IC₅₀: 14 nM			99.88%
Daphnetin	EGFR, IC₅₀: 7.67 μM				99.86%
Gefitinib hydrochloride	EGFR				99.85%
Lifirafenib	EGFR, IC₅₀: 29 nM EGFR^L858R/T790M, IC₅₀: 495 nM				98.73%
Canertinib	EGFR, IC₅₀: 7.4 nM	ErbB2, IC₅₀: 9 nM			99.82%
Chrysophanol	EGFR				99.77%
Pelitinib	EGFR, IC₅₀: 38.5 nM				98.80%
TX1-85-1			ErbB3, IC₅₀: 23 nM		98.04%
Butein	EGFR, IC₅₀: 16 μM (in HepG2 cells)				99.95%
Zanidatamab		HER2
Mubritinib		HER2, IC₅₀: 6 nM			99.91%
Olmutinib	EGFR^{Exon 19 deletion}, IC₅₀: 9.2 nM (Cell Assay) EGFR^L858R/T790M, IC₅₀: 10 nM (Cell Assay)				99.88%
Osimertinib dimesylate	EGFR^L858R, IC₅₀: 12 nM EGFR^L858R/T790M, IC₅₀: 1 nM				99.96%
Sunvozertinib	EGFR exon 20 insertion, IC₅₀: 20.4 nM EGFR^L858R/T790M, IC₅₀: 1.1 nM	Her2 Exon20 YVMA, IC₅₀: 7.5 nM			99.92%
PD153035	EGFR, Ki: 6 pM EGFR, IC₅₀: 25 pM				98.83%
Lapatinib ditosylate	EGFR, IC₅₀: 10.8 nM (Cell Free Assay)	ErbB2, IC₅₀: 9.2 nM (Cell Free Assay)			99.98%
EAI045	EGFR, IC₅₀: 1.9 μM EGFR^L858R, IC₅₀: 0.019 μM EGFR^T790M, IC₅₀: 0.19 μM EGFR^L858R/T790M, IC₅₀: 0.002 μM				99.08%
Zorifertinib	EGFR, IC₅₀: 0.3 nM EGFR^L858R, IC₅₀: 0.2 nM EGFR^{Exon 19 deletion}, IC₅₀: 0.2 nM				99.76%
Gefitinib-based PROTAC 3	EGFR, DC₅₀: 11.7 nM (HCC827(exon 19 del) cells) EGFR, DC₅₀: 22.3 nM (H3255 (L858R mutantion) cells)				99.98%
Rociletinib	EGFR^L858R/T790M, Ki: 21.5 nM EGFR^T790M, Ki: 303.3 nM				99.79%
Pertuzumab (anti-HER2)		HER2			99.10%
Tesevatinib	EGFR, IC₅₀: 0.3 nM	ErbB2, IC₅₀: 16 nM			99.21%
Pyrotinib dimaleate	EGFR, IC₅₀: 13 nM	HER2, IC₅₀: 38 nM			98.56%
Tyrphostin 23	EGFR, IC₅₀: 35 μM (Cell Assay) EGFR, Ki: 11 μM				99.43%
AZ-5104	EGFR^L858R/T790M, IC₅₀: 1 nM EGFR^L858R, IC₅₀: 1 nM EGFR^L861Q, IC₅₀: 6 nM EGFR, IC₅₀: 25 nM			ErbB4, IC₅₀: 7 nM	99.70%
CP-724714		ErbB2, IC₅₀: 10 nM			98.53%
BMS-690514	EGFR, IC₅₀: 5 nM	HER2, IC₅₀: 20 nM		HER4, IC₅₀: 60 nM	99.07%
PD168393	EGFR, IC₅₀: 0.7 nM				98.58%
BI-4020	EGFR^{del19 T790M C797S}, IC₅₀: 0.2 nM EGFR^del19, IC₅₀: 1 nM EGFR^WT, IC₅₀: 190 nM				99.28%
Disitamab		HER2
Zipalertinib	EGFR, IC₅₀: 1.1-8.0 nM				99.81%
Icotinib Hydrochloride	EGFR, IC₅₀: 5 nM				99.81%
Varlitinib	HER1, IC₅₀: 7 nM	HER2, IC₅₀: 2 nM		HER4, IC₅₀: 4 nM	98.03%
Avitinib	EGFR L858R, IC₅₀: 0.18 nM EGFR^T790M, IC₅₀: 0.18 nM EGFR (WT), IC₅₀: 7.68 nM				99.90%
PD158780	EGFR, IC₅₀: 8 μM (Cell Assay)	ErbB2, IC₅₀: 49 nM (Cell Assay)	ErbB3, IC₅₀: 52 nM (Cell Assay)	ErbB4, IC₅₀: 52 nM (Cell Assay)	99.56%
Petosemtamab	EGFR, Kd: 0.22 nM
AEE788	EGFR, IC₅₀: 2 nM	ErbB2, IC₅₀: 6 nM			99.13%
WZ4002	EGFR^L858R, IC₅₀: 2 nM (Cell Assay) EGFR^L858R/T790M, IC₅₀: 8 nM (Cell Assay) EGFR^E746_A750, IC₅₀: 3 nM (Cell Assay) EGFR^{E746_A750/T790M}, IC₅₀: 2 nM (Cell Assay)				99.76%
AG-825	EGFR, IC₅₀: 19 μM	ErbB2, IC₅₀: 0.35 μM			98.02%
TAK-285	EGFR, IC₅₀: 23 nM	HER2, IC₅₀: 17 nM			99.70%
Nazartinib	EGFR^L858R/T790M, Ki: 31 nM				99.03%
JBJ-09-063 hydrochloride	EGFR L858R, IC₅₀: 0.147 nM EGFR L858R/T790M, IC₅₀: 0.063 nM EGFR L858R/T790M/C797S, IC₅₀: 0.083 nM EGFRLT/L747S, IC₅₀: 0.396 nM				99.37%
Rezivertinib	EGFR				99.43%
Tuxobertinib	EGFR, Kd: 0.2 nM	HER2, Kd: 0.76 nM			99.90%
Lumretuzumab			HER3		≥99.0%
Falnidamol	EGFR, IC₅₀: 3 nM	ErbB2, IC₅₀: 3.4 μM			99.05%
Lapatinib ditosylate monohydrate	EGFR, IC₅₀: 10.8 nM	ErbB2, IC₅₀: 9.2 nM			99.93%
Allitinib tosylate	EGFR, IC₅₀: 0.5 nM EGFR^L858R/T790M, IC₅₀: 12 nM	ErbB2, IC₅₀: 3 nM		ErbB4, IC₅₀: 0.8 nM	99.83%
Genistein (Standard)	EGFR				99.31%
WZ-3146	EGFR^L858R, IC₅₀: 2 nM EGFR^L858R/T790M, IC₅₀: 5 nM EGFR^E746_A750, IC₅₀: 2 nM EGFR^{E746_A750/T790M}, IC₅₀: 14 nM EGFR, IC₅₀: 24 nM				99.63%
Avitinib maleate	EGFR (WT), IC₅₀: 7.68 nM EGFR L858R, IC₅₀: 0.18 nM EGFR^T790M, IC₅₀: 0.18 nM				≥98.0%
Canertinib dihydrochloride	EGFR, IC₅₀: 7.4 nM	ErbB2, IC₅₀: 9 nM			99.68%
WHI-P154	EGFR, IC₅₀: 4 nM				99.39%
Naquotinib mesylate	EGFR^L858R/T790M EGFR^L858R EGFR^{Exon 19 deletion} EGFR^{Exon 19 deletion/T790M} EGFR, IC₅₀: 230 nM				98.05%
Mutated EGFR-IN-1	EGFR^L858R EGFR^{Exon 19 deletion/T790M} EGFR^T790M				99.89%
Epertinib hydrochloride	EGFR, IC₅₀: 1.48 ± 0.0 nM	HER2, IC₅₀: 7.15 nM		HER4, IC₅₀: 2.49 ± 0.1 nM	98.25%
MTX-211	EGFR				98.15%
Almonertinib hydrochloride	EGFR^T790M, IC₅₀: 0.37 nM EGFR^L858R/T790M, IC₅₀: 0.29 mM EGFR^{del19 T790M}, IC₅₀: 0.214 nM				99.77%
Neratinib maleate	EGFR, IC₅₀: 92 nM	HER2, IC₅₀: 59 nM			99.83%
Myristicin	EGFR				99.89%
CL-387785	EGFR, IC₅₀: 370 pM				98.05%
Tarloxotinib bromide		EGFR/HER2			99.26%
VEGFR-IN-1	EGFR, IC₅₀: 0.24 μM				98.42%
Mobocertinib succinate	EGFR exon 20 insertion EGFR (WT)	HER2			99.83%
limertinib	EGFR^T790M, IC₅₀: 0.5 nM EGFR^L858R/T790M, IC₅₀: 0.3 nM EGFR (WT), IC₅₀: 6 nM EGFR^{Exon 19 deletion}, IC₅₀: 0.5 nM				99.12%
BI-4142		HER2, IC₅₀: 5 nM			98.39%
Simotinib	EGFR, IC₅₀: 19.9 nM				99.39%
(Rac)-JBJ-04-125-02	EGFR (L858R/T790M), IC₅₀: 0.26 nM
MS154	EGFR (WT), Kd: 1.8 nM EGFR^L858R, Kd: 3.8 nM				99.42%
PD153035 Hydrochloride	EGFR, Ki: 6 pM EGFR, IC₅₀: 25 pM				99.48%
HKI-357	EGFR, IC₅₀: 34 nM	ErbB2, IC₅₀: 33 nM			99.65%
Tarlox-TKI	EGFR				98.84%
EGFR/ErbB-2/ErbB-4 inhibitor-3	ErbB1, IC₅₀: 0.3 nM EGFR, IC₅₀: 2.5 nM	ErbB2, IC₅₀: 1.1 nM		ErbB4, IC₅₀: 0.5 nM	98.19%
HG-14-10-04	EGFR^LR/TM, IC₅₀: 15.6 nM EGFR^19del/TM/CS, IC₅₀: 22.6 nM EGFR^LR/TM/CS, IC₅₀: 124.5 nM				99.09%
Bafisontamab	EGFR
Naquotinib	EGFR, IC₅₀: 230 nM				98.71%
Larotinib mesylate hydrate	EGFR (WT), IC₅₀: 0.611 nM EGFR^L858R, IC₅₀: 0.563 nM EGFR^L861Q, IC₅₀: 0.423 nM EGFR^T790M, IC₅₀: 45.2 nM	HER2, IC₅₀: 253 nM		HER4, IC₅₀: 84 nM	98.66%
BI-1622		HER2, IC₅₀: 7 nM			98.97%
JBJ-09-063 TFA	EGFR L858R, IC₅₀: 0.147 nM EGFR L858R/T790M, IC₅₀: 0.063 nM EGFR L858R/T790M/C797S, IC₅₀: 0.083 nM EGFRLT/L747S, IC₅₀: 0.396 nM				99.64%
Oritinib	EGFR (WT), IC₅₀: 18 nM EGFR^L858R, IC₅₀: 0.7 nM EGFR^L861Q, IC₅₀: 4 nM EGFR^L858R/T790M, IC₅₀: 0.1 nM EGFR^d746-750, IC₅₀: 1.4 nM EGFR^{d746-750/T790M}, IC₅₀: 0.89 nM				99.18%
EGFR/ErbB-2/ErbB-4 inhibitor-2	EGFR, IC₅₀: 0.017 μM	ErbB2, IC₅₀: 0.08 μM		ErbB4, IC₅₀: 1.91 μM	99.45%
AG-494	EGFR, IC₅₀: 0.7 μM				99.31%
PD-161570	EGFR, IC₅₀: 240 nM				99.82%
PF-6274484	EGFR (WT), Ki: 0.18 nM EGFR^L858R/T790M, Ki: 0.14 nM				98.76%
MS9449	EGFR (WT), Kd: 17 nM EGFR L858R, Kd: 10 nM				98.95%
WHI-P180	EGFR, IC₅₀: 4 μM				99.62%
EGFR-IN-12	EGFR (WT), IC₅₀: 21 nM EGFR^L858R, IC₅₀: 63 nM EGFR^L861Q, IC₅₀: 4 nM			HER4, IC₅₀: 7640 nM	99.40%
Piperonylic acid	EGFR				99.91%
Anbenitamab		Human HER2			99.22%
Selatinib	EGFR, IC₅₀: 13 nM	ErbB2, IC₅₀: 22.5 nM			99.83%
PROTAC EGFR degrader 2	EGFR, DC₅₀: 36.51 nM
GW2974	EGFR^L858R/T790M, IC₅₀: 0.007 μM	HER2, IC₅₀: 0.016 μM			99.54%
AV-412 free base	EGFR, IC₅₀: 0.75 nM EGFR^L858R, IC₅₀: 0.51 nM EGFR^L858R/T790M, IC₅₀: 2.3 nM EGFR^T790M, IC₅₀: 0.79 nM	ErbB2, IC₅₀: 19 nM			98.33%
TAS0728	EGFR, IC₅₀: 65 nM	HER2, IC₅₀: 13 nM		HER4, IC₅₀: 8.5 nM	99.15%
Theliatinib	EGFR, IC₅₀: 3 nM EGFR, Ki: 0.05 nM EGFR (L858R/T790M), IC₅₀: 22 nM				99.77%
EGFR-IN-11	EGFR^{L858R/T790M/C797S}, IC₅₀: 18 nM				99.30%
Rociletinib hydrobromide	EGFR^L858R/T790M, Ki: 21.5 nM EGFR^T790M, Ki: 303.3 nM				98.04%
Tyrphostin AG 528	EGFR, IC₅₀: 4.9 μM	ErbB2, IC₅₀: 2.1 μM			≥98.0%
PD-089828	EGFR, IC₅₀: 5.47 μM EGFR, Ki: 3.16 μM				98.07%
RG14620	EGFR, IC₅₀: 3 μM (Cell Assay)				98.09%
Mutant EGFR inhibitor	EGFR^L858R EGFR^{Exon 19 deletion} EGFR^T790M				99.51%
CGP52411	EGFR, IC₅₀: 0.3 μM				99.82%
CNX-2006	EGFR^T790M, IC₅₀: 20 nM				98.42%
(E)-AG 99	EGFR				98.36%
EGFR-IN-7	EGFR (WT), IC₅₀: 7.92 nM EGFR (C797S/T790M/L858R), IC₅₀: 0.218 nM				99.76%
Cinrebafusp alfa		HER2, Kd: 0.3 nM			98.53%
EGFR-IN-5	EGFR, IC₅₀: 10.4 nM EGFR^L858R, IC₅₀: 1.1 nM EGFR^L858R/T790M, IC₅₀: 34 nM EGFR^{L858R/T790M/C797S}, IC₅₀: 7.2 nM				98.64%
PROTAC EGFR degrader 9	EGFR^{L858R/T790M/C797S}, DC₅₀: 10.2 nM EGFR^{L858R/T790M/C797S}, Kd: 240.2 nM EGFR^{del19 T790M C797S}, DC₅₀: 36.5 nM EGFR^L858R/T790M, DC₅₀: 88.5 nM EGFR^del19, DC₅₀: 75.4 nM EGFR (WT), DC₅₀: >300 nM				98.35%
Lavendustin C	EGFR, IC₅₀: 0.012 μM				98.32%
AG 555	EGFR				≥98.0%
Astragaloside VI	EGFR				99.95%
EGFR-IN-89	EGFR^19del/TM/CS, IC₅₀: 10.1 nM
EGFR/HER2-IN-9	EGFR, IC₅₀: 3.2 nM EGFR^T790M, IC₅₀: 8.3 nM	HER2, IC₅₀: 14 nM			98.73%
EGFR kinase inhibitor 3	EGFR (WT), IC₅₀: <10 nM EGFR L858R, IC₅₀: 1.5 nM EGFR L858R/T790M, IC₅₀: 0.059 nM EGFR L858R/T790M/C797S, IC₅₀: 0.064 nM
JNJ28871063 hydrochloride	ErbB1, IC₅₀: 22 nM	ErbB2, IC₅₀: 38 nM		ErbB4, IC₅₀: 21 nM	98.36%
EMI1	EGFR^{del19 T790M C797S} EGFR^{L858R/T790M/C797S}				99.78%
NRC-2694	EGFR				99.45%
PROTAC EGFR degrader 7	EGFR^L858R/T790M, DC₅₀: 13.2 nM				99.99%
AV-412	EGFR, IC₅₀: 0.75 nM EGFR^L858R, IC₅₀: 0.5 nM EGFR^T790M, IC₅₀: 0.79 nM EGFR^L858R/T790M, IC₅₀: 2.3 nM	ErbB2, IC₅₀: 19 nM			99.17%
ZD-4190	EGFR				98.08%
Epertinib	EGFR, IC₅₀: 1.48 ± 0.0 nM	HER2, IC₅₀: 7.15 ± 0.5 nM		HER4, IC₅₀: 2.49 ± 0.1 nM	≥98.0%
Firmonertinib	EGFR				99.89%
MC-Val-Cit-PAB-Amide-TLR7 agonist 4		HER2			99.39%
EGFR-IN-1 hydrochloride	EGFR^L858R/T790M
EGFR-IN-1	EGFR^L858R/T790M
MS9427	EGFR (WT), Kd: 7.1 nM EGFR L858R, Kd: 4.3 nM
JBJ-09-063	EGFR L858R, IC₅₀: 0.147 nM EGFR L858R/T790M, IC₅₀: 0.063 nM EGFR L858R/T790M/C797S, IC₅₀: 0.083 nM EGFRLT/L747S, IC₅₀: 0.396 nM
Mutated EGFR-IN-3	EGFR^L858R/T790M, IC₅₀: 12 nM EGFR^C797S, IC₅₀: 13 nM
JBJ-04-125-02	EGFR (L858R/T790M), IC₅₀: 0.26 nM
DBPR112	EGFR^L858R/T790M, IC₅₀: 48 nM EGFR^WT, IC₅₀: 15 nM				98.37%
(S)-Sunvozertinib	EGFR exon 20 NPH, IC₅₀: 51.2 nM EGFR exon 20 ASV insertion, IC₅₀: 51.9 nM EGFR^L858R/T790M, IC₅₀: 1 nM	Her2 exon 20 YVMA insertion, IC₅₀: 21.2 nM			99.14%
EGFR-IN-17	EGFR (C797S/T790M/L858R), IC₅₀: 0.0002 μM				98.42%
Larotinib	EGFR (WT), IC₅₀: 0.611 nM EGFR^L858R, IC₅₀: 0.563 nM EGFR^L861Q, IC₅₀: 0.423 nM EGFR^T790M, IC₅₀: 45.2 nM	HER2, IC₅₀: 253 nM		HER4, IC₅₀: 84 nM	99.50%
SU5204		HER2, IC₅₀: 51.5 μM			99.46%
pan-HER-IN-2	EGFR, IC₅₀: 0.72 nM EGFR (L858R/T790M), IC₅₀: 8.2 nM	HER2, IC₅₀: 75.1 nM		HER4, IC₅₀: 2.0 nM	98.10%
YS-363	EGFR, IC₅₀: 0.96 nM				99.52%
EGFR-IN-1 TFA	EGFR^L858R/T790M				99.38%
HX103	EGFR^del19, IC₅₀: 1.3 nM EGFR^L858R, IC₅₀: 1.5 nM EGFR^T790M, IC₅₀: 977 nM EGFR^WT, IC₅₀: 4.0 nM				99.10%
Inetetamab		HER2
EGFR-IN-69	EGFR L858R/T790M/C797S, IC₅₀: 4.3 ± 0.9 nM EGFR^L858R/T790M, IC₅₀: 6.6 ± 0.8 nM EGFR^{del19 T790M C797S}, IC₅₀: 25.6 ± 7.5 nM EGFR^WT, IC₅₀: 816.0 ± 82 nM				99.58%
T-1-PMPA	EGFR^WT, IC₅₀: 86 nM EGFR^T790M, IC₅₀: 561.73 nM				99.70%
ZM 449829	EGFR, pIC₅₀: 5.0				99.73%
Nazartinib mesylate	EGFR^L858R/T790M, Ki: 31 nM
BGB-102	EGFR, IC₅₀: 9.6 nM	HER2, IC₅₀: 18 nM		HER4, IC₅₀: 40.3 nM	99.52%
Allitinib	EGFR, IC₅₀: 0.5 nM EGFR^L858R/T790M, IC₅₀: 12 nM	ErbB2, IC₅₀: 3 nM		ErbB4, IC₅₀: 0.8 nM	99.36%
Afatinib oxalate	EGFR^L858R, IC₅₀: 0.4 nM EGFR^WT, IC₅₀: 0.5 nM EGFR^L858R/T790M, IC₅₀: 10 nM	HER2, IC₅₀: 14 nM
JBJ-02-112-05	EGFR^L858R/T790M, IC₅₀: 15 nM
Mobocertinib mesylate	EGFR exon 20 insertion EGFR (WT)	HER2
Lapatinib tosylate	EGFR, IC₅₀: 10.2 nM	ErbB2, IC₅₀: 9.8 nM
EGFR/CSC-IN-1	EGFR, IC₅₀: 10.52 nM
ZN-A-1041		HER2
TX2-121-1			HER3, IC₅₀: 49 nM
Mutated EGFR-IN-2	EGFR (L858R/T790M), IC₅₀: <1 nM
Oritinib mesylate	EGFR (WT), IC₅₀: 18 nM EGFR^L858R, IC₅₀: 0.7 nM EGFR^L861Q, IC₅₀: 4 nM EGFR^L858R/T790M, IC₅₀: 0.1 nM EGFR^d746-750, IC₅₀: 1.4 nM EGFR^{d746-750/T790M}, IC₅₀: 0.89 nM
EMI56	EGFR^{L858R/T790M/C797S} EGFR^{del19 T790M C797S}				99.72%
EMI48	EGFR^{L858R/T790M/C797S} EGFR^{del19 T790M C797S}				99.02%
EGFR-IN-15	EGFR, IC₅₀: 4 nM
EGFR/HER2-IN-2	EGFR, IC₅₀: 5.02 μM	HER2, IC₅₀: 0.83 μM
Sacibertinib	EGFR-TK phosphorylation, EC₅₀: 110 nM	HER2, EC₅₀: 244 nM
Gancotamab		HER2
SU 5402 (GMP)	EGFR, IC₅₀: 30 nM
HER2-IN-5		HER2
EGFR-IN-36	EGFR (WT), IC₅₀: 19.09 nM	HER2(WT), IC₅₀: 120.01 nM HER2 (A775_G776insYVMA), IC₅₀: 2.35 nM
EGFR/BRAF-IN-1	EGFR
Gamendazole		ErbB2
pan-HER-IN-1	EGFR, IC₅₀: 0.38 nM EGFR^{L858R/T790M/C797S}, IC₅₀: 2.2 nM	HER2, IC₅₀: 3.5 nM		HER4, IC₅₀: 1.6 nM
BMS-599626 dihydrochloride	HER1, IC₅₀: 20 nM	HER2, IC₅₀: 30 nM
EGFR-IN-74	EGFR^L858R/T790M, IC₅₀: 138 nM
EGFR/HER2-IN-5	EGFR, IC₅₀: 0.6 nM	HER2, IC₅₀: 0.6 nM
HER2-IN-12		HER2, IC₅₀: 121 nM
EGFR-IN-92	EGFR L858R/T790M
Multi-kinase-IN-4		HER2, IC₅₀: 0.18 mM
GLUT1/EGFR-IN-1	EGFR
Chrysophanol (Standard)	EGFR
EGFR/C797S-IN-1	EGFR^{L858R/T790M/C797S}, IC₅₀: 0.128 μM
PROTAC EGFR degrader 5	EGFR, DC₅₀: 34.8 nM
HER2-IN-8		HER2
EGFR-IN-46	EGFR, IC₅₀: 20.17 nM
(E/Z)-CP-724714		HER2
PDE5-IN-3	EGFR, IC₅₀: 5.827 μM
EGFR WT/T790M-IN-2	EGFR^T790M, IC₅₀: 0.08 μM EGFR^WT, IC₅₀: 0.13 μM
EGFR/HER2-IN-10	EGFR, IC₅₀: 2.3 nM	HER2, IC₅₀: 234 nM
EGFR-IN-60	EGFR, IC₅₀: 0.083 μM EGFR^L858R, IC₅₀: 0.053 μM EGFR^T790M, IC₅₀: 0.026 μM
JGK-068S	EGFR
EGFR T790M/L858R-IN-4	EGFR^L858R/T790M
EGFR-IN-62	EGFR^L858R/T790M, IC₅₀: 10 ± 1 EGFR (WT), IC₅₀: 29 ± 2 EGFR^{L858R/T790M/C797S}, IC₅₀: 242 ± 9
EGFR-IN-52	EGFR, IC₅₀: 0.358 μM EGFR^L858R, IC₅₀: 86.02 μM EGFR^T790M, IC₅₀: 432.67 μM
EGFR-IN-3	EGFR^WT, IC₅₀: 0.32 μM
EGFR-IN-80	EGFR, pIC₅₀: 10.6
EGFR-IN-49	EGFR^T790M, IC₅₀: 65.0 nM EGFR^L858R/T790M, IC₅₀: 13.6 nM
EGFR-IN-73	EGFR^del19, IC₅₀: 119 nM EGFR^L858R, IC₅₀: 820 nM EGFR^WT, IC₅₀: >10 μM EGFR^L858R/T790M, IC₅₀: >10 μM
EGFR-IN-106	EGFR, IC₅₀: 0.2396 μM
EGFR ligand-2	EGFR^L858R, IC₅₀: 21 nM EGFR^L858R/T790M, IC₅₀: 48 nM
EGFR-IN-124	EGFR, IC₅₀: 0.54 μM
EGFR T790M/L858R-IN-2	EGFR^L858R/T790M, IC₅₀: 3.5 nM EGFR (WT), IC₅₀: 1290 nM EGFR^T790M, IC₅₀: 6.7 nM EGFR^L858R, IC₅₀: 2.1 nM				99.66%
TAS-121	EGFR L858R, IC₅₀: 1.7 nM EGFR (ex19del), IC₅₀: 2.7 nM EGFR L858R/T790M, IC₅₀: 0.56 nM EGFR (ex19del/T790M), IC₅₀: 1.1 nM EGFR (WT), IC₅₀: 8.2 nM	HER2, IC₅₀: 110 nM		HER4, IC₅₀: 2.6 nM
EGFR-IN-21	EGFR, IC₅₀: 0.38 nM
MJ04	EGFR, IC₅₀: 3267 nM
EGFR-IN-28	EGFR
EGFR/HER2/TS-IN-2	EGFR, IC₅₀: 0.173 ± 0. μM	HER2, IC₅₀: 0.125 ± 0. μM
EGFR/HER2-IN-4	EGFR, IC₅₀: 0.6 nM
EGFR-IN-55	EGFR^L858R/T790M, IC₅₀: 3.9 nM EGFR^WT, IC₅₀: 70 nM
EGFR-IN-116	EGFR, IC₅₀: 0.103 μM
EGFR/HER2-IN-3	EGFR	HER2
EGFR-IN-29	EGFR^T790M
EGFR-IN-133	EGFR (WT), IC₅₀: 0.1 nM
EGFR-IN-22	EGFR^{L858R/T790M/C797S}, IC₅₀: 0.54 nM EGFR (WT), IC₅₀: 4.91 nM
EGFR-IN-75	EGFR^WT, IC₅₀: 0.28 μM EGFR^T790M, IC₅₀: 5.02 μM
RET-IN-19	EGFR, IC₅₀: 56.78 ± 4. μM
DPPY	EGFR, IC₅₀: <10 nM
HER2-IN-18	EGFR (WT), IC₅₀: 500-1500 n nM	HER2(WT), IC₅₀: <200 nM HER2 YVMA, IC₅₀: <200 nM
HSP90-IN-13	EGFR, IC₅₀: 38.5 nM
HER2-IN-9		HER2, IC₅₀: 0.03 μM
EP26	EGFR, IC₅₀: 48.6 nM
EGFR kinase inhibitor 1	EGFR (WT), IC₅₀: 37 nM EGFR^L858R/T790M, IC₅₀: 1.7 nM EGFR^{L858R/T790M/C797S}, IC₅₀: >300 nM
EGFR-IN-56	EGFR^T790M, IC₅₀: 541.7 nM EGFR^L858R/T790M, IC₅₀: 132.1 nM
HER2-IN-20	EGFR (WT), IC₅₀: 4584 nM	HER2(WT), IC₅₀: 49 nM HER2 YVMA, IC₅₀: 42 nM
EGFR-IN-27	EGFR^del19, IC₅₀: <50 nM EGFR^L858R, IC₅₀: <50 nM EGFR^L858R/T790M, IC₅₀: <50 nM EGFR^{del19 T790M C797S}, IC₅₀: <50 nM EGFR (C797S/T790M/L858R), IC₅₀: <50 nM EGFR^{del19 T790M}, IC₅₀: <50 nM
EGFR-IN-115	EGFR, IC₅₀: 395.2 nM
HER2-IN-17		Her2 exon 20 YVMA insertion, IC₅₀: <200 nM
EGFR/HER2-IN-15	EGFR (WT), IC₅₀: 37.21 nM
EGFR-IN-30	EGFR (WT), IC₅₀: 1-10 nM EGFR (L858R/T790M/C797S), IC₅₀: <1 nM
HER2-IN-13	EGFR (WT), IC₅₀: 0.40 μM	HER2, IC₅₀: 8 nM
EGFR-IN-127	EGFR^ex19del, IC₅₀: 136.3 nM EGFR^19del/TM/CS, IC₅₀: 161.2 nM
Simotinib hydrochloride	EGFR, pIC₅₀: 19.9 nM
PD 173955 analog 1	EGFR, IC₅₀: 0.19 μM
EGFR/HER2/DHFR-IN-3	EGFR, IC₅₀: 0.138 μM	HER2, IC₅₀: 0.092 μM
EGFR-IN-57	EGFR, IC₅₀: 0.054 μM
EGFR-IN-16	EGFR, pIC₅₀: 4.85	HER2, pIC₅₀: 4.74
EGFR-IN-109	EGFR, IC₅₀: 25.8 nM EGFR^T790M, IC₅₀: 182.3 nM
HER2-IN-15		Her2 exon 20 YVMA insertion, IC₅₀: <200 nM
EGFR-IN-67	EGFR, IC₅₀: 0.34 μM
EGFR/VEGFR2-IN-3	EGFR, IC₅₀: 0.129 μM
EGFR-IN-134	EGFR, IC₅₀: 0.023 μM
HER2-IN-16		Her2 exon 20 YVMA insertion, IC₅₀: <200 nM
EGFR-IN-64	EGFR, IC₅₀: 0.33 μM
EGFR-IN-54	EGFR, IC₅₀: 1.623 μM
EGFR-IN-9	EGFR (WT), IC₅₀: 7 nM EGFR^L858R/T790M, IC₅₀: 28 nM				98.84%
EGFR/HER2-IN-16	EGFR, IC₅₀: 6.15 nM HER1, IC₅₀: 9.78 nM
EGFR/HER2/TS-IN-1	EGFR, IC₅₀: 0.203 μM	HER2, IC₅₀: 0.088 μM
HER2-IN-14	EGFR (WT), IC₅₀: 6.3 μM	HER2, IC₅₀: 18 nM
Multi-kinase-IN-6	EGFR, IC₅₀: 0.1 μM
Tyrphostin 8	EGFR, IC₅₀: 560 μM				≥98.0%
EGFR-IN-105		ErbB2, : 0.68 μM
EGFR-IN-45	EGFR, IC₅₀: 0.4 μM
2′-Thioadenosine		ErbB2, IC₅₀: 45 μM
EGFR-IN-40	EGFR, IC₅₀: 5.3 nM
EGFR-IN-53	EGFR, IC₅₀: 8.264 μM
EGFR-IN-51	EGFR, IC₅₀: 0.493 μM EGFR^L858R, IC₅₀: 102.60 μM EGFR^T790M, IC₅₀: 461.63 μM
EGFR-IN-131	EGFR, IC₅₀: 272.9 nM
EGFR-IN-61	EGFR^L858R/T790M, IC₅₀: 42 ± 2 nM EGFR^{L858R/T790M/C797S}, IC₅₀: 137 ± 6 nM EGFR (WT), IC₅₀: 743 ± 20 nM
AG-1478 hydrochloride	EGFR, IC₅₀: 3 nM
EGFR kinase inhibitor 7	EGFR, IC₅₀: 42.3 nM
EGFR-IN-132	EGFR (WT), IC₅₀: 1.6 nM
EGFR-IN-120	EGFR^{L858R/T790M/C797S}, IC₅₀: 0.053 μM
EGFR-IN-104	EGFR^L858R/T790M, IC₅₀: 0.33 μM EGFR^{L858R/T790M/C797S}, IC₅₀: 0.133 μM
EGFR T790M/L858R-IN-6	EGFR (L858R/T790M)
CHMFL-EGFR-202	EGFR^T790M, IC₅₀: 5.3 nM EGFR, IC₅₀: 8.3 nM	ErbB2, IC₅₀: 8.1 nM		ErbB4, IC₅₀: 3.2 nM	99.75%
Nelipepimut-S		HER2
WHI-P180 hydrochloride	EGFR, IC₅₀: 4 μM
Trastuzumab rezetecan		HER2
Herceptide		HER2
GW837016X		ErbB2
Calotatug ginistinag		HER2
SHR-A1201		HER2
Erlotinib mesylate	EGFR, IC₅₀: 2 nM
SU-4313	EGFR, IC₅₀: 11 μM	HER2, IC₅₀: 16.9 μM
D-69491 hydrochloride		HER2
Neptinib	EGFR (WT), IC₅₀: 0.24 nM EGFR^L858R/T790M, IC₅₀: 7.25 nM EGFR^L858R, IC₅₀: 0.46 nM EGFR^T790M, IC₅₀: 1.79 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.